Aardvark Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AARD Nasdaq 2834 aardvarktherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aardvark Therapeutics, Inc.

Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold - May 14th, 2026 2:01 pm
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - May 7th, 2026 6:00 am
Discover 3 Promising Penny Stocks With Market Caps Over $100M - Apr 17th, 2026 6:05 am
Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings - Mar 29th, 2026 2:42 pm
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Mar 23rd, 2026 2:05 pm
A Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO Trial - Mar 4th, 2026 7:21 pm
Aardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety Questions - Mar 3rd, 2026 5:22 pm
Why Aardvark Therapeutics Just Lost More Than Half Its Value - Mar 2nd, 2026 2:28 pm
Sector Update: Health Care Stocks Retreat Late Afternoon - Mar 2nd, 2026 1:58 pm
Safety concerns spur Aardvark to halt key Prader-Willi drug trial - Mar 2nd, 2026 1:26 am
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome - Feb 27th, 2026 2:05 pm
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 13th, 2026 6:00 am
Aardvark Therapeutics Announces Leadership Appointments - Feb 12th, 2026 6:00 am
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer - Feb 12th, 2026 6:00 am
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome - Feb 10th, 2026 6:00 am
Aardvark Therapeutics, Inc. (NASDAQ:AARD) stock most popular amongst retail investors who own 32%, while private equity firms hold 28% - Jan 19th, 2026 12:08 pm
Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls - Dec 23rd, 2025 7:33 am
Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win - Dec 11th, 2025 2:27 pm
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome - Dec 10th, 2025 2:05 pm
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December - Nov 25th, 2025 2:05 pm